3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year

Pfizer (forward yield 6.7%) is highlighted for pipeline expansion—notably in oncology—AI-driven cost cuts and an agreement with the U.S. administration that exempts it from tariffs in exchange for price reductions, supporting dividend sustainability. Bristol Myers Squibb (4.6% yield) is benefiting from recent launches and a subcutaneous Opdivo formulation that preserves exclusivity to smooth upcoming patent cliffs. Medical Properties Trust (7.1% yield) has recovered after a major tenant bankruptcy by replacing tenants and refinancing debt, though it previously cut dividends twice; all three are presented as income-oriented plays with improving fundamentals but remaining risks.

Analysis

Market structure: Large-cap pharma (PFE, BMY) and healthcare REITs (MPW) are the direct beneficiaries of income-seeking flows as bond yields stay elevated; PFE gains from AI-driven cost cuts and oncology launches while MPW benefits from tenant diversification and refinancings. Losers include smaller, single-product biotechs facing patent cliffs and any peers exposed to expanded drug-price controls; the administration pact that limits tariffs in exchange for price concessions reduces pricing power and shifts some value capture to payers.

Risk assessment: Tail risks include accelerated regulatory price controls (national policy moves within 12–24 months), a new major tenant bankruptcy at MPW, or a failed late-stage oncology readout at PFE (high-impact within 3–9 months). Short-term (days–weeks) focus on dividend confirmations and refinance announcements; medium-term (3–12 months) on FDA readouts and quarterly sales trends; long-term (1–3 years) on patent cliffs and label-expansion success. Hidden dependencies: PFE’s cost-savings hinge on successful AI deployments and M&A cadence; MPW’s recovery depends on refinancing windows and interest-rate moves.

Trade implications: Favor selective income-oriented longs with hedges: PFE as a core 2–3% portfolio position (12-month horizon) given 6.7% forward yield and pipeline optionality; MPW sized smaller (1–2%) with downside protection because REIT valuations are highly rate-sensitive (a 100bp rise in yields can compress NAV by ~5–8%). Use covered-call overlays on PFE to harvest yield and 6–12 month protective puts on MPW to cap tail risk. Rotate 1–2% out of cyclicals into healthcare income over the next 3 months, and tighten stop-losses around dividend announcements.

Contrarian angles: Consensus underweights operational leverage at PFE — a steady stream of oncology approvals plus 5–10% SG&A reduction from AI could convert current yield into capital-return optionality, making dividend sustainable. Conversely, MPW’s high yield likely still discounts refinancing and liquidity risk — the market may be underestimating covenant or cap-exposure on remaining legacy assets. Historical parallel: post-patent cliff pharma recoveries (2016–2019) show 12–24 month rebounds when new franchises scale; but policy-driven price compression would break that script and is the primary asymmetric downside.

Key Decisions for Investors

• Establish a 2–3% long position in PFE with a 12-month target; enhance income by selling 3-month covered calls ~8–12% OTM each quarter. If quarterly EPS misses by >8% or Pfizer announces a dividend cut, reduce to ≤1% within 48 hours.
• Deploy a tactical 1–2% position in MPW via shares paired with 6–12 month protective puts 10–15% OTM to limit downside; unwind or hedge further if occupancy falls below 85% or >$250M of debt remains unrefinanced within 6 months.
• Implement a pair trade: go long PFE (2%) and short BMY (1.5%) to express relative stability/yield vs. execution risk; close the short if BMY posts two consecutive quarters of >10% YoY revenue beat from label expansions or if PFE announces material negative trial results.
• Rotate 1–2% of portfolio from cyclicals into healthcare income (PFE/MPW) over the next 60–90 days and maintain a 2–3% cash buffer. If U.S. drug-price policy proposals advance (committee vote or White House signals within 30–90 days), reduce pharma exposure by 50% and increase fixed-income hedge allocation.